Press coverage about RadNet (NASDAQ:RDNT) has trended somewhat positive on Friday, Accern Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. RadNet earned a news sentiment score of 0.07 on Accern’s scale. Accern also gave news coverage about the medical research company an impact score of 43.1912489605793 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

RadNet (NASDAQ:RDNT) traded up 0.219% during mid-day trading on Friday, hitting $11.425. 429,532 shares of the stock were exchanged. The company has a market cap of $540.01 million, a P/E ratio of 60.132 and a beta of 0.95. The company has a 50-day moving average price of $10.66 and a 200-day moving average price of $7.93. RadNet has a one year low of $5.25 and a one year high of $11.90.

RadNet (NASDAQ:RDNT) last announced its quarterly earnings data on Tuesday, August 8th. The medical research company reported $0.11 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.04 by $0.07. RadNet had a net margin of 1.04% and a return on equity of 19.98%. The firm had revenue of $230.00 million during the quarter, compared to analysts’ expectations of $230.32 million. During the same quarter last year, the business earned $0.09 earnings per share. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. Analysts forecast that RadNet will post $0.30 earnings per share for the current fiscal year.

A number of brokerages have weighed in on RDNT. BidaskClub upgraded shares of RadNet from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 24th. Jefferies Group LLC raised shares of RadNet from a “hold” rating to a “buy” rating and boosted their target price for the stock from $7.00 to $12.00 in a research note on Tuesday, August 22nd. TheStreet raised shares of RadNet from a “c” rating to a “b-” rating in a research note on Thursday, August 24th. Finally, Zacks Investment Research cut shares of RadNet from a “hold” rating to a “sell” rating in a research note on Wednesday. One analyst has rated the stock with a sell rating, one has issued a hold rating, one has given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $12.00.

TRADEMARK VIOLATION NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact RadNet (RDNT) Stock Price” was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark laws. The original version of this news story can be accessed at

In other RadNet news, insider Stephen M. Forthuber sold 18,500 shares of RadNet stock in a transaction dated Monday, August 21st. The shares were sold at an average price of $8.38, for a total transaction of $155,030.00. Following the completion of the transaction, the insider now owns 406,922 shares in the company, valued at $3,410,006.36. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Sandy Nyholm Kaminsky sold 1,100,000 shares of RadNet stock in a transaction dated Tuesday, October 3rd. The stock was sold at an average price of $10.95, for a total transaction of $12,045,000.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,236,900 shares of company stock valued at $13,452,504. 9.36% of the stock is currently owned by company insiders.

About RadNet

RadNet, Inc is a provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States. As of December 31, 2016, the Company operated directly or indirectly through joint ventures, 305 centers located in California, Delaware, Florida, Maryland, New Jersey, New York and Rhode Island.

Insider Buying and Selling by Quarter for RadNet (NASDAQ:RDNT)

Receive News & Ratings for RadNet Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.